Stock MBRX MOLECULIN BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Moleculin Biotech, Inc.

Equities

MBRX

US60855D3098

Real-time Estimate Cboe BZX
Other stock markets
 02:04:09 2024-04-29 pm EDT 		5-day change 1st Jan Change
5.215 USD +12.63% Intraday chart for Moleculin Biotech, Inc. +22.09% -59.23%
Apr. 18 Sector Update: Health Care Stocks Ease in Afternoon Trading MT
Apr. 18 Moleculin Biotech Secures Orphan Drug Label For Annamycin in EU MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
European Medicines Agency Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia
AQ
Sector Update: Health Care Stocks Ease in Afternoon Trading
MT
Moleculin Biotech Secures Orphan Drug Label For Annamycin in EU
MT
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
PR
Top Premarket Decliners
MT
Transcript : Moleculin Biotech, Inc. - Special Call
Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference
PR
Moleculin to Participate in the Virtual Investor Lunch Break, the Moleculin Opportunity
AQ
Sector Update: Health Care Stocks Advance Late Afternoon
MT
Sector Update: Health Care
MT
Moleculin Biotech Shares Rise Following Patent Announcement
MT
Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity
PR
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML
PR
Maxim Adjusts Price Target on Moleculin Biotech to $20 From $45, Maintains Buy Rating
MT
Moleculin Reports Full Year 2023 Financial Results
AQ
Transcript : Moleculin Biotech, Inc., 2023 Earnings Call, Mar 25, 2024
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
PR
Moleculin Biotech, Inc Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
CI
Moleculin Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MBRX Stock
  4. News Moleculin Biotech, Inc.